Find a company
Stroke due to large vessel occlusion (LVO) contributes very significantly towards global adult disability and care costs. This burden is reduced when a specialist surgical treatment (thrombectomy) is performed rapidly within the first 6 hours. However most patients are first admitted to a local hospital, which cannot provide treatment. Suitable patients must be transferred onto the nearest thrombectomy centre, delaying treatment by ~2 hours, with corresponding poorer outcomes.
Our technology could allow LVO detection in ambulances, enabling direct admission of selected patients to thrombectomy centres.
Having previously demonstrated 95% accuracy for LVO detection using laboratory assays, we are developing a portable blood test. We will validate the test on biobank of samples and collect feedback from end-users and stroke survivors.
| Project | A point-of-care blood test for the pre-hospital identification of stroke patients suitable for emergency thrombectomy treatment |
|---|---|
| Description |
Stroke due to large vessel occlusion (LVO) contributes very significantly towards global adult disability and care costs. This burden is reduced when a specialist surgical treatment (thrombectomy) is performed rapidly within the first 6 hours. However most patients are first admitted to a local hospital, which cannot provide treatment. Suitable patients must be transferred onto the nearest thrombectomy centre, delaying treatment by ~2 hours, with corresponding poorer outcomes. Our technology could allow LVO detection in ambulances, enabling direct admission of selected patients to thrombectomy centres. Having previously demonstrated 95% accuracy for LVO detection using laboratory assays, we are developing a portable blood test. We will validate the test on biobank of samples and collect feedback from end-users and stroke survivors. |
| Funding | £ 881,931 |
| Competition | Competition 18 - Stroke and Technology |
| Competition Date | June 2021 |
| Categories | Stroke , Blood |
| Health Innovation Network Partner | Health Innovation North East and North Cumbria |
| Website | http://www.upfrontdiagnostics.com/ |
Stroke due to large vessel occlusion (LVO) contributes very significantly towards global adult disability and care costs. This burden is reduced when a specialist surgical treatment (thrombectomy) is performed rapidly within the first 6 hours. However most patients are first admitted to a local hospital, which cannot provide treatment. Suitable patients must be transferred onto the nearest thrombectomy centre, delaying treatment by ~2 hours, with corresponding poorer outcomes.
Our technology could allow LVO detection in ambulances, enabling direct admission of selected patients to thrombectomy centres.
Having previously demonstrated 95% accuracy for LVO detection using laboratory assays, we are developing a portable blood test. We will validate the test on biobank of samples and collect feedback from end-users and stroke survivors.
| Project | Real-world evidence for NHS adoption of a point-of-care blood-test for pre-hospital identification of stroke patients suitable for thrombectomy treatment (LVOne-Pathway) |
|---|---|
| Description |
LVOne is a novel rapid blood test for diagnosing severe stroke patients who need rapid treatment with mechanical thrombectomy. By using only a small fingerstick sample of blood, the test measures 2 protein biomarkers that the company has discovered, validated, and patented. LVOne is designed to be used in ambulance, so that patients can be identified early and fast-tracked to treatment. This project will investigate: 1) barriers/facilitators of LVOne's implementation in the real-world, 2) Accuracy for identification of treatment eligibility and not just clinical condition, 3) Health economics. |
| Funding | £ 500,000 |
| Competition | Competition 26 - Stroke |
| Competition Date | July 2024 |
| Categories | Stroke |
| Health Innovation Network Partner | Health Innovation North East and North Cumbria |
| Website | http://www.upfrontdiagnostics.com/ |